Sorrento Therapeutics Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin (RTX) for Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
September 26, 2022 09:00 ET
|
Sorrento Therapeutics, Inc.
Phase 2 trial of RTX for OAK pain completed enrollment with last patient (n=120) dosedNo limiting toxicities have been encountered during the trial to date. Patients are now being monitored for...
Canadian Military Veterans Complete Hike to Bring Awareness to Chronic Pain
August 30, 2022 07:32 ET
|
Chronic Pain Centre of Excellence for Canadian Veterans
HAMILTON, Ontario, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Seven military Veterans living with chronic pain from across Canada completed the first-ever Military Veterans Alpine Challenge (Alpine...
Peripheral Nerve Stimulation Pioneer Dr. Marc Huntoon Joins SPR Therapeutics as Director of Medical Affairs
August 02, 2022 16:23 ET
|
SPR Therapeutics, Inc.
CLEVELAND, Aug. 02, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics is proud to announce the addition of Dr. Marc Huntoon to the company as Director of Medical Affairs. In this role, he will provide...
SPR Therapeutics to Present Clinical Trial and Real-World Findings at ASPN 2022
July 14, 2022 10:54 ET
|
SPR Therapeutics, Inc.
CLEVELAND, July 14, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics announced today that two presentations highlighting SPRINT® PNS in treating chronic pain will be featured at the American Society of...
Global Neuromodulation Market to Reach $4.3 Bn Globally, by 2030, at 6.2% CAGR: Says AMR
June 15, 2022 07:47 ET
|
Allied Market Research
Portland, OR, June 15, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Neuromodulation Market was estimated at $2.48 billion in 2020, and is...
Medical Case Management Market Size Worth $5.22Bn, Globally, by 2028 at 3.5% CAGR - Exclusive Report by The Insight Partners
April 25, 2022 14:06 ET
|
The Insight Partners
New York, April 25, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Medical Case Management Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Mode of...
Prolonged Temporary Neurostimulation Treatment Period Offered by the SPRINT® PNS System May Optimize Pain Management Care Pathway While Reducing Healthcare Costs
March 15, 2022 10:31 ET
|
SPR Therapeutics, Inc.
CLEVELAND, March 15, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics announced publication of a study in the Journal of Pain Research demonstrating how a longer initial treatment period may better...
HealthCheck360 Partners With Fern Health to Provide Digital Solutions for Chronic Musculoskeletal Pain
February 07, 2022 08:00 ET
|
HealthCheck360
DUBUQUE, Iowa, Feb. 07, 2022 (GLOBE NEWSWIRE) -- HealthCheck360, a leader in population health management and well-being programs for employers, is expanding its program to address the underlying...
RespireRx Pharmaceuticals Inc. Announces Publication of a Manuscript Describing Its Newest Neuromodulator for Pharmacoresistant Epilepsy and Chronic Pain
January 24, 2022 07:00 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Jan. 24, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
The PNS Trifecta: All Three SPRINT® PNS System Abstracts Submitted to ASRA 2021 Pain Medicine Meeting Receive President’s Choice Award
November 18, 2021 12:32 ET
|
SPR Therapeutics, Inc.
CLEVELAND, Nov. 18, 2021 (GLOBE NEWSWIRE) -- SPR Therapeutics has been honored with three President’s Choice Abstract Awards at the 20th Annual ASRA Pain Medicine Meeting taking place November 18-20...